Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 13Terminated 7Recruiting 5Active not recruiting 4Withdrawn 2Unknown 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

Cyclophosphamide 26Rituximab 22Biopsy 17Specimen Handling 16Prednisone 15Magnetic Resonance Spectroscopy 14Doxorubicin 14fludarabine 12Vincristine 12fludarabine phosphate 9Etoposide 7Bendamustine Hydrochloride 7Tacrolimus 6Nuclear Medicine Department, Hospital 6Melphalan 6trametinib 5acalabrutinib 5X-Rays 5Whole-Body Irradiation 5Radiotherapy 5Mycophenolic Acid 5Lenalidomide 5Crizotinib 5pembrolizumab 4ibrutinib 4copanlisib 4Prednisolone 4Mesna 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma × pembrolizumab × Clear all
NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Presage Biosciences

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Recurrence

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

University of Chicago

Phase 2 Active not recruiting
51 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05878691 2024-07-22

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Glenmark Specialty S.A.

Phase 1 Active not recruiting
320 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡